z-logo
Premium
in vitro thermo‐chemosensitivity screening of spontaneous human tumors: Significant potentiation for cisplatin but not adriamycin
Author(s) -
Calabro Annamaria,
Eva Singletary S.,
Tucker Susan,
Boddie Arthur,
Spitzer Gary,
Cavaliere Renato
Publication year - 1989
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910430306
Subject(s) - cisplatin , chemosensitivity assay , doxorubicin , medicine , in vitro , hyperthermia , toxicity , pharmacology , bone marrow , drug , chemotherapy , chemistry , biochemistry
The in vitro thermal enhancement of Adriamycin (ADR) and Cisplatin (CDDP) was investigated in 18 surgical biopsy specimens of human tumors cultured in the Adhesive Tumor Cell Culture System. Experimental conditions were adopted to simulate “therapeutic” trials: (a) temperature of 37.0°C, 40.5°C or 42.5°C; (b) hyperthermic duration of 30, 60, or 120 min; and (c) 4‐dose drug range normalized to human bone marrow toxicity. Drug concentrations that inhibited 90% of tumor growth (IC 90 ) at 37.0°C were compared to the IC 90 at 40.5°C and 42.5°C, adjusted for the effect of heat alone. CDDP plus heat was a better combination than ADR plus heat, regardless of the temperature and the exposure duration: significant synergism ( p < 0.001) occurred in 37% of heat‐CDDP combinations, as compared with 15% of heat‐ADR combinations, and antagonism was significantly lower ( p < 0.001) for heat‐CDDP than for heat‐ADR (4.4% versus 21% of combinations, respectively). Within the CDDP group, higher temperature and longer heat exposure resulted in an increased incidence of chemosensitivity. No specific pattern of synergism was evident within the ADR group, but a trend toward a higher incidence of antagonistic effects with increasing hyperthermic duration was observed.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here